logo-loader

MGC Pharmaceuticals says 'next step is to convert our efforts in research into commercial revenue'

Published: 21:10 07 Apr 2021 AEST

MGC Pharmaceuticals Ltd's (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) (FRA:H5O) Roby Zomer talks to Proactive's Katie Pilbeam about the completed delivery of their first bulk order in March of ArtemiCTM Rescue to Swiss PharmaCan AG.

He says the 'next step is to convert efforts in research into commercial revenue and take our company towards profitability.... now we're ready'.

The deal equates to around $425,000 (€275,000) in wholesale production revenue to the company. Zomer sales it's time to move all of this development into sales and build a sales team globally.

MGC Pharmaceuticals reveals strategic objectives for H1 2024

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) CEO and Managing Director Roby Zomer speaks to Thomas Warner from Proactive London following the completion of a share consolidation and capital raise. With these restructuring initiatives completed, Zomer shares his enthusiasm for the...

on 14/11/23